Global Clinical Trial Disclosure: What Noncompliance Penalties Are in Place, & How They Are Enforced
White paper
薬事規制関連支援サービス
In the wake of the coronavirus pandemic, pressure has come from regulatory agencies, the public, patients, advocates, pharmaceutical industry watchdogs, and investors for increased clinical transparency. This white paper takes a look at a broad spectrum of global disclosure regulations, whether penalties exist for noncompliance and, if so, whether they are being enforced.
Failure to register and fully report clinical trials harms patients, wastes taxpayers’ money, and slows down the development of new treatments, vaccines and cures.
